SCHEMBL7150599

SCHEMBL7150599

O=C(C1CC(S)CN1S(=O)(=O)c1ccc2ccccc2c1)N1CCC(O)CC1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ECE1 P42892 4/20 0.55
MME P08473 2/20 0.55
ACE P12821 2/20 0.55
AKR1C3 P42330 4/20 0.47
AKR1C1 Q04828 1/20 0.46
KMT2A Q03164 1/20 0.45
EIF2AK3 Q9NZJ5 1/20 0.44
HCRTR1 O43613 1/20 0.44
HCRTR2 O43614 1/20 0.44
LMNA P02545 3/20 0.43
TSHR P16473 2/20 0.43
USP2 O75604 1/20 0.43
MAPK1 P28482 1/20 0.43
HSD17B10 Q99714 1/20 0.43
MCOLN3 Q8TDD5 3/20 0.43
ALDH1A1 P00352 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
F2 P00734 1/20 0.42
CCR4 P51679 1/20 0.42
PKM P14618 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7150595 1.00 ECE1 (0.55) ECE1MMEACEAKR1C3AKR1C1
SCHEMBL7135958 0.90 AKR1C3 (0.57) ECE1MMEACEAKR1C3AKR1C1
SCHEMBL7145236 0.90 AKR1C3 (0.57) ECE1MMEACEAKR1C3AKR1C1
SCHEMBL7143498 0.90 AKR1C3 (0.57) ECE1MMEACEAKR1C3AKR1C1
SCHEMBL7143508 0.90 AKR1C3 (0.57) ECE1MMEACEAKR1C3AKR1C1
SCHEMBL7151655 0.89 ECE1 (0.56) ECE1MMEACEAKR1C3AKR1C1
SCHEMBL7151653 0.89 ECE1 (0.56) ECE1MMEACEAKR1C3AKR1C1
SCHEMBL7135751 0.84 KMT2A (0.68) ECE1MMEACEKMT2ALMNA
SCHEMBL7142130 0.84 KMT2A (0.68) ECE1MMEACEKMT2ALMNA
SCHEMBL7135749 0.84 KMT2A (0.68) ECE1MMEACEKMT2ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1303485-A1 PYRROLIDINE DERIVATIVES AS INHIBITORS OF ENDOTHELIN-CONVERTING ENZYME F. HOFFMANN-LA ROCHE AG (CH) 2003-04-23 EP disclosed
US-6541638-B2 (2S,4S)-1-(4-Mercapto-1-(naphthalene-2-sulfonyl)-pyrrolidine-2 -carbonyl)-piperidine-4-carboxylic acid ethyl ester for example; zinc protease inhibitors; for treating diseases associated with vasoconstriction HOFFMAN-LA ROCHE INC. 2003-04-01 US disclosed
US-20020049243-A1 Pyrrolidine derivatives HOFFMANN-LA ROCHE INC. 2002-04-25 US disclosed
WO-2002006222-A1 PYRROLIDINE DERIVATIVES AS INHIBITORS OF ENDOTHELIN-CONVERTING ENZYME F. HOFFMANN-LA ROCHE AG (CH) 2002-01-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020049243-A1 Pyrrolidine derivatives PREP, PEPD, DNPEP ECE1 4/4885MME 99/4885ACE 44/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.